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case-finding in coeliac disease
Alina Popp1,2,4*, Mariana Jinga1,3, Ciprian Jurcut3, Vasile Balaban3, Catalina Bardas2, Kaija Laurila4, Florina Vasilescu3,
Adina Ene2, Ioana Anca1,2 and Markku Mäki4Abstract
Background: Coeliac disease (CD), due to its protean clinical manifestation, is still very under diagnosed in adults
and delays in diagnosis may take years and even decades. Simple tools to find cases in primary care may help to
identify patients for further diagnostic tests. We have evaluated the usefulness of an on site rapid fingertip whole
blood point-of-care test (POCT) for such a purpose.
Methods: As CD is known to run within families, we tested 148 healthy relatives of 70 Romanian index cases with
biopsy-proven CD (87% of all first-degree family members, median age 36 years) for the presence of circulating
autoantibodies. In addition to performing the POCT (which measures blood erythrocyte self-TG2-autoantibody
complexes) on site, blood was drawn for later evaluations of serum IgA-class endomysial antibodies (EMA).
EMA-positive sera were further tested for transglutaminase 2 antibodies (TG2-IgA). All serological parameters were
analyzed blindly in a centralized laboratory that had no knowledge of the on site POCT result. Endoscopic small
intestinal biopsies was recommended for all POCT- or EMA-test positive subjects.
Results: In on site testing the POCT was positive in 12/148 first-degree relatives (8%) and all these subjects were also
serum EMA-positive. A positive EMA test was found only in one other subject. All remaining 135 healthy first-degree
relatives were negative for both POCT and EMA. Four subjects positive for both POCT and EMA were negative for
TG2-IgA. Ten out of thirteen of the antibody-positive subjects agreed to undergo endoscopy. The POCT was found to
be positive in 8/9 first-degree relatives having coeliac-type mucosal lesions of grade Marsh 2 (n = 3) or Marsh 3 (n = 6).
The three POCT-positive subjects not agreeing to undergo endoscopy were also both EMA- and TG2-IgA-positive.
Conclusion: The fingertip whole blood rapid POCT might fulfill the unmet need for a simple and cheap case-finding
biomarker for early detection and presumptive diagnosis of CD. Confirmatory studies are warranted in adult
case-finding in specialized outpatient clinics and in primary care.
Keywords: Coeliac disease, Healthy relatives, Case-finding, Point-of-care testBackground
Coeliac disease (CD) is a systemic disorder triggered by
the ingestion of gluten, a protein present in wheat, rye
and barley. Gluten injures the small intestinal mucosal
lining leading to villous atrophy and crypt hyperplasia
[1]. Individuals affected by the disease also share the
autoimmune extended human leukocyte antigen (HLA)
haplotypes DR3-DQ2, DR11/7-DQ2 or DR4-DQ8. The* Correspondence: alina.popp@uta.fi
1University of Medicine and Pharmacy “Carol Davila”, Str. Dionisie Lupu nr.
37, sector 1, 020022 Bucharest, Romania
2Institute for Mother and Child Care “Alfred Rusescu”, Bdv. Lacul Tei nr. 120,
sector 2, 020395 Bucharest, Romania
Full list of author information is available at the end of the article
© 2013 Popp et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orprevalence of CD in various populations is around 1%
[2,3] but there are countries with lower and higher
prevalence [4]. There is also evidence that the disease
itself is increasing over time, similar to other autoimmune
diseases in general [5-8]. CD manifests at all ages. It may
be clinically silent, patients may show only vague symp-
toms or present with extraintestinal problems including
psychiatric, neurologic, bone, liver or reproductive disor-
ders or as malignancy [9-12].
It is well known that CD runs within families, and
first-degree relatives of patients are at risk of developing
the disorder [13-15]. By reason of the protean manifest-
ation of CD, clinical suspicion is not obvious, and it istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wide [1,4,7,16]. Even if health professionals are aware of
diagnostic delays, this period of latency persists and is
counted in years and decades [17-19]. Screen-detected
patients with clinically silent disease but manifest small-
intestinal mucosal lesion seem to benefit from a gluten-
free diet [20-22]. It has in fact been claimed that CD
detected by screening is not silent but simply unrecognized
[23]. Also new CD management models include first-
degree relatives as a high-risk group and recommend
case-finding screening within families [24].
Active case-finding in primary care using sensitive and
specific biomarkers of CD might be a solution to shorten
diagnostic delays. Centralized laboratories provide auto-
antibody tests such as endomysial (EMA) and antitrans-
glutaminase 2 (TG2) IgA antibody tests [25,26]. However,
centralized laboratory tests are not easily available or
affordable for medical health care in many parts of the
world. An easy-to-use on site whole blood self-TG2-based
fingertip point-of-care test (POCT) has been shown to
be effective in CD case finding in schoolchildren at a
population-based level and in children with type 1 dia-
betes [21,27]. The POCT proved to be highly sensitive
and specific resulting in an accuracy of >95% to detect
untreated CD [28]. Also, a recent evidence report showed
the POCT to have a high pooled sensitivity and specificity
in case finding of CD [26]. We hypothesize that a less
invasive and less expensive POCT biomarker is able to
pick out clinically silent CD in adults in a low-prevalence
population. To test this hypothesis we chose to study CD
families where the disease would be expected to be preva-
lent among first-degree relatives.
Methods
Patients
170 first-degree healthy relatives of 70 index cases (77
children and 15 adults) were invited over a five years
period (2007–2012) to be evaluated for the presence of
coeliac-autoantibodies. The inclusion criterion for the
index cases was biopsy-proven CD (Marsh 3 mucosal
lesion). Of the 170 subjects, 148 (18 children, 130 adults;
median age 36 years, range 1.2-77) agreed to participate.
The remaining 22 could not been reached or declined. At
the time of the evaluation, all participants confirmed that
they were consuming a regular gluten-containing diet.
Whole blood and serum case-finding biomarkers
The screening for the presence of CD autoantibodies in
the healthy relatives took place on the same day as the
diagnostic examinations of the index patients or in certain
cases later, during regular follow-up visits. All centralized
laboratory serologic determinations were made in blinded
fashion without knowledge of the on-site fingertip whole
blood POCT results.The Biocard Celiac Test, AniBiotech, Vantaa, Finland,
was selected as the point-of-care biomarker test for CD
case-finding. This rapid whole blood self TG2-based
IgA-class fingertip test uses the patient’s own endogenous
TG2 found in the erythrocytes of a whole blood sample.
When the finger-tip blood is haemolyzed, the liberated
TG2 forms a complex with circulating autoantibodies,
if present in the same sample. Blood erythrocyte self-
TG2-autoantibody complexes are captured from the
haemolyzed sample by TG2-binding proteins onto a
solid phase and the presence of autoantibodies is mea-
sured by labeled antihuman IgA [28]. The results of the
POCT were evaluated visually on site after five mi-
nutes, but no later than ten minutes, according to the
manufacturer’s recommendations (line visible in test
window – positive result; no line in test window –
negative result).
On the same day when the POCT was performed,
venous blood was drawn for laboratory serum autoanti-
body measurements. Serum IgA-class antiendomysial
antibodies (EMA) were determined using an indirect
immunofluorescence method (Nova Lite, Inova Diagnos-
tics, CA, USA) with cut-off for positivity at a serum di-
lution of 1:5. Further serum dilutions (1:50, 1:100,
1:200, 1:500, 1:1000, 1:2000, 1:4000) were made for ini-
tial positive samples till the highest positive titer was
obtained for each sample. In the present series, no cases of
selective IgA deficiency were found.
Serum samples showing positivity in the EMA test
were further evaluated for TG2-IgA (Celikey, Phadia
GmbH, Freiburg, Germany) using an enzyme-linked
immunosorbent assay (ELISA) with a positivity cut-off at
5 U/ml, as recommended by the product manufacturer.Endoscopy and biopsies
Upper gastrointestinal endoscopy with small-bowel
mucosal biopsies was recommended for all subjects
with positive POCT or EMA tests. During endoscopy,
up to 5 duodenal mucosal specimens were taken. The
biopsy specimens were fixed in formalin, embedded in
paraffin, cut, stained with haematoxylin-eosin and
scored by pathologists (AE and FV) according to the
Marsh-Oberhuber classification (Marsh 0, 1, 2, 3a, 3b,
or 3c) [29,30].Ethics approval
The study was approved by the Ethical Committee of
the University and Pharmacy “Carol Davila” and Ethical
Committee of the Institute for Mother and Child Care
“Alfred Rusescu” Bucharest, Romania. The antibody-
positive subjects or their parents gave written informed
consent for upper gastrointestinal endoscopy.
Popp et al. BMC Gastroenterology 2013, 13:115 Page 3 of 5
http://www.biomedcentral.com/1471-230X/13/115Results
In total, 12 out of 148 (8%) first-degree healthy relatives
showed positivity in the POCT. All POCT-positive sub-
jects proved to be EMA-positive, giving 100% specificity
for the POCT against the reference standard for serum
CD autoantibody [24]. Only one more positive subject
was found by the EMA test (Table 1) and all the
remaining 135 healthy first-degree relatives were nega-
tive both in the POCT and for EMA.
Altogether 10/13 antibody positive family members
were adults (median age 38.5 years). Four subjects posi-
tive for both POCT and EMA were negative for TG2-
IgA when using the manufacturer’s positivity cut-off of
5 U/ml. When again using 3 U/ml as cut-off, as suggested
by the new ESPGHAN 2012 criteria [24], only one
EMA-positive subject would have been missed by the
ELISA method. Her EMA titre was low, 1:5, but she was
also POCT-positive (case 4 in Table 1). The only EMA-
positive subject, case 7 in Table 1, with a low serum titer
of 1:50 and yielding a negative test result in POCT, had
a TG2-IgA titer of 4.2 U/ml.
Ten of the thirteen antibody-positive first-degree rela-
tives agreed to undergo upper gastrointestinal endoscopy
and duodenal biopsies. All but one showed coeliac-type
mucosal lesions of grade Marsh 2 (n = 3) and Marsh 3
(n = 6), as summarized in Table 1. POCT was found to
be positive in eight of the nine subjects with biopsy-
proven CD. The three POCT-positive subjects not agree-
ing to undergo endoscopy also showed marked positivityTable 1 Spectrum of coeliac type serum autoantibodies
and small-intestinal mucosal biopsy outcome in healthy
first-degree relatives of coeliac disease (CD) patients
Case
no.
Gender Age at CD
antibody
evaluation
(years)
POCT EMA-IgA
(serum
dilution
step)
TG2-
IgA
(U/ml)
Biopsy
outcome
(Marsh
classification)
1 F 39 + 1:4000 821.5 3c
2 F 38 + 1:200 37.4 NA
3 F 36 + 1:1000 61.8 NA
4 F 34 + 1:5 2.3 3b
5 F 40 + 1:2000 499.4 NA
6 F 42 + 1:200 25.6 1
7 F 56 - 1:50 4.2 2
8 F 2.4 + 1:50 3.4 3a
9 M 10.7 + 1:5 3.5 2
10 F 36 + 1:50 4.0 3a
11 F 46 + 1:4000 40.2 3c
12 F 31 + 1:200 21.4 2
13 F 2 + 1:1000 72.8 3c
Abbreviations: F female, M male, NA not available, POCT point of care test,
EMA antiendomysial antibody, TG2-IgA IgA class transglutaminase 2 antibodies.in both EMA and TG2-IgA tests (Table 1). The preva-
lence of coeliac gluten sensitivity was 8.7% as deter-
mined by positive autoantibodies.
Discussion
The present study emphasizes the usefulness of a simple
rapid fingertip whole blood POCT for a presumptive
diagnosis of CD. The test was able to select correctly
individuals, even clinically silent ones, for further con-
firmatory diagnostic studies such as duodenal biopsies.
We show that the POCT tested on site worked hand in
hand with the centralized laboratory golden standard
CD autoantibody testing, the EMA test [24]; among 148
tested subjects there was only one discrepant result, a
POCT-negative person who had a low serum EMA titer
but who was also negative for TG2-IgA (case No. 7 in
Table 1). Furthermore, gluten-induced small intestinal
mucosal lesion, i.e. Marsh class 2 and 3, was detected in
all but one of the biopsied subjects. From this series of
individuals we also noted that even low titers of EMA
positivity may be indicative of mucosal injury.
To confirm or disprove our hypothesis that the used
POCT biomarker is able to pick out CD also in adults,
we chose to study first-degree family members of CD
patients. In fact, 77% of the family members positive for
the test were adults and our results are in agreement
with those previously obtained in children [21,27,28].
The present POCT results also confirm the results of a
recent report where POCT was shown to have a pooled
sensitivity of 96.4% and pooled specificity of 97.7% for
detection of CD [26]. The same report showed the cen-
tralized hospital ELISA TG2-IgA in 11/15 studies to
have a sensitivity of >90% and in 13/15 studies a specifi-
city of >90%. ELISA testing for the presence of TG2-IgA
seems to lead to false-positive results especially in indi-
viduals carrying a high risk of CD such as relatives of
patients [31]. As reviewed by Husby et al. [24], TG2-
IgA positivity without CD is also seen in autoimmune
disorders, in patients with infections, tumors, psoriasis
and heart and liver diseases. The epitopes in TG2 for
the false-positive antibodies in other diseases and seen
in ELISA tests differ from the TG2 epitopes which CD
patient autoantibodies target. Further, positive TG2-IgA
ELISA results in patients without CD do not correlate
with the EMA results [32].
On-site use of the POCT seems to provide a strong
tool for the health care system in case-finding of CD.
This offers immediate results and potentially shortens
the diagnostic process in adults [17-19]. Moreover, the
use of a POCT in primary care might lower the costs
related to equipment, trained personnel and time-man-
agement of centralized serological tests. As of now, a
small-intestinal biopsy is still needed for confirmation of
diagnosis. But on the other hand, the present study
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that TG2-IgA can be assessed in the physician’s office by
using the self antibody-based rapid finger-tip test, and in
areas with limited resources a rapid test may be used as
sole diagnostic means for CD [33].
A limitation in the present study is the relatively small
population studied. The study should be repeated in
larger adult patient populations in primary care and
specialized outpatient clinics dealing with patients with
vague and various symptoms or signs where CD could
be the underlying cause of ill health.
The serologic prevalence of CD in our study in
Romania was 8.7%, similar to that reported in other
family studies [13-15]. The present results argue, similarly
to a recent case-finding study in type 1 diabetes [27], that
the CD prevalence in Romania is probably much higher
than previously thought. In fact, there has previously been
an indication that the disease exists in adults in Romania,
unspecific symptoms have shown a frequent small-
intestinal mucosal injury indicative of CD [34]. Overall,
the POCT seems to work as well as the EMA test in case
identification [14]. A recent Austrian study indicates that
the POCT is a reliable, easy to use and well-accepted tool
even for home testing of first- and second-degree relatives
of patients with CD [35].
Conclusion
In conclusion, case-finding in the primary care using a
fingertip whole blood on site POCT could be the way
forward in the early detection and diagnosis of celiac
disease.
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